Nektar Therapeutics (NASDAQ: NKTR)

Nektar Therapeutics is a clinical-stage biopharmaceutical company specializing in the discovery and development of innovative immunotherapies. The company focuses on creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve therapeutic outcomes in autoimmune diseases and oncology. Nektar applies its deep expertise in immunology to identify and advance drug candidates through preclinical and clinical development, with a pipeline centered on novel mechanisms to address unmet medical needs.

The company generates revenue primarily through collaboration agreements, royalties, and milestone payments from partnered drug programs. Historically, Nektar earned manufacturing revenue and product sales from its proprietary polyethylene glycol (PEG) reagents, though it sold its manufacturing facility in December 2024. Following the termination of its collaboration with Eli Lilly and Company for rezpegaldesleukin, Nektar no longer receives collaboration-based revenues for its lead drug candidates unless new partnerships are established. Royalties from previously partnered products, such as ADYNOVATE, MOVANTIK, and CIMZIA, continue to contribute to revenue.

The company operates through the following segments:

• Autoimmune Diseases: This segment focuses on developing therapies to restore immune balance in patients with autoimmune and inflammatory disorders. The lead candidate, rezpegaldesleukin, is a first-in-class resolution therapeutic designed to stimulate regulatory T cells (Tregs) by targeting the interleukin-2 (IL-2) receptor complex. Rezpegaldesleukin is being evaluated in Phase 2b trials for moderate-to-severe atopic dermatitis and severe-to-very-severe alopecia areata, with Fast Track designation granted by the FDA for both indications. Additional preclinical programs, NKTR-0165 and NKTR-0166, target the tumor necrosis factor receptor type II (TNFR2) pathway for autoimmune diseases like ulcerative colitis and multiple sclerosis.

• Oncology: This segment aims to activate the body’s natural tumor-fighting mechanisms through immune system modulation. The lead candidate, NKTR-255, is an investigational biologic targeting the interleukin-15 (IL-15) pathway to enhance natural killer (NK) cell and CD8+ memory T cell function. NKTR-255 is being evaluated in combination with cell therapies and checkpoint inhibitors in clinical collaborations with institutions such as Fred Hutchinson Cancer Center and Merck KGaA. The program is designed to sustain durable anti-tumor immune responses in cancers like large B-cell lymphoma and urothelial carcinoma.

• Preclinical and Discovery Programs: This segment includes early-stage research initiatives leveraging Nektar’s polymer conjugate technology and immunology expertise. Programs such as NKTR-422, a PEG-modified colony-stimulating factor 1 (CSF1) candidate, target inflammation and fibrosis. The company also explores novel drug candidates across proteins, peptides, and antibodies to expand its pipeline.

Nektar Therapeutics occupies a niche position within the biopharmaceutical industry, competing in the immunotherapy space with a focus on selective immune modulation. In autoimmune diseases, rezpegaldesleukin competes with cytokine-based, microbiome-based, and regulatory T cell therapies from companies like Regeneron, Eli Lilly, Sanofi, and AstraZeneca. In oncology, NKTR-255 faces competition from engineered IL-15 biologics and cell therapies developed by ImmunityBio, Nkarta, and Roche. The company’s competitive advantages include its proprietary polymer conjugate technology, which enhances drug pharmacokinetics and safety profiles, and its deep immunology expertise. However, Nektar operates in a highly competitive landscape with larger pharmaceutical companies possessing greater financial and commercial resources.

The company’s customer base primarily consists of pharmaceutical and biotechnology partners, healthcare providers, and patients. Historically, Nektar derived significant revenue from collaborations with partners such as Takeda Pharmaceuticals, AstraZeneca, UCB Pharma, and Pfizer, which commercialized products incorporating its PEGylation technology. Following the sale of its manufacturing facility, Nektar’s revenue streams shifted toward royalties and milestone payments. For its proprietary drug candidates, the company targets patients with autoimmune diseases and cancer, though commercialization will depend on regulatory approvals and potential future partnerships.